Peter Ellmark
21 – 30 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
- Contribution to journal › Article
-
Mark
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
- Contribution to journal › Article
- 2016
-
Mark
Selective FcγR engagement by human agonistic anti-CD40 antibodies
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity.
- Contribution to journal › Article
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
- Contribution to journal › Article
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
- Contribution to journal › Article
- 2009
-
Mark
Attovial-based antibody nanoarrays.
- Contribution to journal › Article
- 2008
-
Mark
Detection of pancreatic cancer using antibody microarray-based serum protein profiling
- Contribution to journal › Article
-
Mark
Multiplexed Lipid Dip-Pen Nanolithography on Subcellular Scales for the Templating of Functional Proteins and Cell Culture
- Contribution to journal › Article
